Skip to main content

Telomir Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

TELO$0.57-17.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30,
20262025
Cash flows from Operating activities:
Net loss$(2,712,475)$(7,249,718)
Adjustments to reconcile net loss to net cash used in operations
Stock-based compensation expense238,5376,040,136
Stock-based compensation expense – stock option modification587,737—
Change in operating assets and liabilities:
Prepaid expenses(140,929)(17,415)
Trade accounts payable and accrued liabilities(341,242)(332,580)
Accrued compensation - officer(417,470)—
Net cash used in operating activities(2,785,842)(1,559,577)
Cash flows from Financing activities:
Repayment to officer(155,518)—
Proceeds from issuance of insurance loan payable224,789—
Repayments on insurance loan payable(88,416)—
Proceeds from TELI contribution, related party1,000,000—
Repayment of payable to related party(317,708)—
Net proceeds from sale of common stock in ATM6,311—
Proceeds from sale of common stock—1,047,769
Net cash provided by financing activities669,4581,047,769
Net change in cash(2,116,384)(511,808)
Cash, beginning of period7,286,6701,266,131
Cash, end of period$5,170,286$754,323
Supplemental disclosure of cash flow information:
Cash paid for interest$5,045$—
Cash paid for income tax$—$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.